Sunday - December 22, 2024

Use of ADAMTS13 for Treating, Ameliorating and/or Preventing Vaso-Occlusive Crisis in Sickle Cell Disease, Acute Lung Injury and/or Acute Respiratory Distress Syndrome

2024-12-03

ALEXANDRIA, Virginia, Dec. 3 -- TAKEDA PHARMACEUTICAL COMPANY LIMITED, Osaka, Japan has been assigned a patent (No. US 12156903 B2, initially filed Nov. 1, 2021) developed by five inventors Bruce Ewenstein, Brookline, Massachusetts; Brahm Goldstein, Cambridge, Massachusetts; Bernhard Majer, Vienna, Austria; Paolo Rossato, Vienna, Austria; and Marietta Turecek, Mauerbach, Austria, for "Use of ADAMTS13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acut . . .

Information Request Form

Name:
Category that best fits the type of business or agency you are affiliated with:	Government Newspaper / Media Business Public Policy Individual / Student Educators
Company Name:
Email:
Phone:
State:

I'd like to have a copy of this article mailed to me.

To also receive a free sample of other Targeted News products check the appropriate boxes below.
Golf Handicap site (FairwayFiles.com)
Products marked with ** can be customized by keywords or areas of interest. If you select them please specify your keywords in the box below:

If we need to contact you please specify your preferred contact method. Have a representative contact me by phone
Have a representative contact me via email

Additonal questions or comments:

Click here for more information or a free trial

Existing Customer Login

Use of ADAMTS13 for Treating, Ameliorating and/or Preventing Vaso-Occlusive Crisis in Sickle Cell Disease, Acute Lung Injury and/or Acute Respiratory Distress Syndrome

Information Request Form

Copyright Targeted News Service 2024